P. Fajtova

Development of subunit selective proteasome substrates for Schistosoma species

The paper develops subunit-specific proteasome substrates for Schistosoma species, showing improved performance and cross-species applicability.

Structural elucidation of recombinant Trichomonas vaginalis 20S proteasome bound to covalent inhibitors

This study determines the cryo-EM structures of recombinant Trichomonas vaginalis 20S proteasome bound to covalent inhibitors, revealing their binding modes and explaining inhibitor specificity.

Development of subunit selective substrates for Trichomonas vaginalis proteasome

The paper develops three subunit-specific fluorogenic substrates for the T. vaginalis proteasome and identifies effective inhibitor targets.

Development of Highly Selective Epoxyketone-based Plasmodium Proteasome Inhibitors with Negligible Cytotoxicity

This study develops highly selective epoxyketone-based proteasome inhibitors effective against Plasmodium falciparum with low cytotoxicity to human cells.

Large library docking for novel SARS-CoV-2 main protease non-covalent and covalent inhibitors

The paper identifies novel non-covalent and covalent inhibitors of SARS-CoV-2 main protease through virtual docking and experimental validation.

Structure-based identification of naphthoquinones and derivatives as novel inhibitors of main protease Mpro and papain-like protease PLpro of SARS-CoV-2

This study identifies naphthoquinone derivatives as inhibitors of SARS-CoV-2 proteases Mpro and PLpro through virtual screening and biochemical assays.

Potent in vitro anti-SARS-CoV-2 activity by gallinamide A and analogues via inhibition of cathepsin L

A cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cells

This paper shows that K777, a cysteine protease inhibitor, blocks SARS-CoV-2 infection by inhibiting host cathepsin L, which is required for spike protein processing, with nanomolar efficacy in several cell lines.